Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
Lung cancer is one of the deadliest types of cancer responsible for thousands of cancer-related deaths. Its treatment has remained a challenge for researchers, but an increase in the knowledge of molecular pathways and biology of lung cancer has dramatically changed its management in recent decades....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1014156/full |
| _version_ | 1818016613718294528 |
|---|---|
| author | Reem Altaf Reem Altaf Sarmad Sheraz Jadoon Syed Aun Muhammad Umair Ilyas Yongtao Duan |
| author_facet | Reem Altaf Reem Altaf Sarmad Sheraz Jadoon Syed Aun Muhammad Umair Ilyas Yongtao Duan |
| author_sort | Reem Altaf |
| collection | DOAJ |
| description | Lung cancer is one of the deadliest types of cancer responsible for thousands of cancer-related deaths. Its treatment has remained a challenge for researchers, but an increase in the knowledge of molecular pathways and biology of lung cancer has dramatically changed its management in recent decades. Immunotherapies and immunomodulation of lung cancer have previously failed for a long time but thanks to continuous research work and enthusiasm, now, this field is emerging as a novel effective therapy. Now, it is hope with potential benefits and promising results in the treatment of lung cancer. This review article focuses on immune checkpoints inhibitors: CTLA-4 inhibitors (ipilimumab and tremelimumab) and PDL-1 inhibitors (durvalumab and atezolizumab) that can be blocked to treat lung carcinoma. It is also focused on critically analyzing different studies and clinical trials to determine the potential benefits, risks, and adverse events associated with immunotherapeutic treatment. |
| first_indexed | 2024-04-14T07:14:58Z |
| format | Article |
| id | doaj.art-a12a08a55799422484952596c18e4902 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T07:14:58Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a12a08a55799422484952596c18e49022022-12-22T02:06:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.10141561014156Recent advances in immune checkpoint inhibitors for non-small lung cancer treatmentReem Altaf0Reem Altaf1Sarmad Sheraz Jadoon2Syed Aun Muhammad3Umair Ilyas4Yongtao Duan5Henan Provincial Key Laboratory of Children’s Genetics and Metabolic Diseases, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Pharmacy, Iqra University Islamabad Campus, Islamabad, PakistanState Key Laboratory of Esophageal Cancer Prevention and Treatment, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaInstitute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, PakistanDepartment of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, PakistanHenan Provincial Key Laboratory of Children’s Genetics and Metabolic Diseases, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaLung cancer is one of the deadliest types of cancer responsible for thousands of cancer-related deaths. Its treatment has remained a challenge for researchers, but an increase in the knowledge of molecular pathways and biology of lung cancer has dramatically changed its management in recent decades. Immunotherapies and immunomodulation of lung cancer have previously failed for a long time but thanks to continuous research work and enthusiasm, now, this field is emerging as a novel effective therapy. Now, it is hope with potential benefits and promising results in the treatment of lung cancer. This review article focuses on immune checkpoints inhibitors: CTLA-4 inhibitors (ipilimumab and tremelimumab) and PDL-1 inhibitors (durvalumab and atezolizumab) that can be blocked to treat lung carcinoma. It is also focused on critically analyzing different studies and clinical trials to determine the potential benefits, risks, and adverse events associated with immunotherapeutic treatment.https://www.frontiersin.org/articles/10.3389/fonc.2022.1014156/fulllung cancerimmune checkpoint inhibitorsimmunotherapynon-small lung cancerchemotherapy |
| spellingShingle | Reem Altaf Reem Altaf Sarmad Sheraz Jadoon Syed Aun Muhammad Umair Ilyas Yongtao Duan Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment Frontiers in Oncology lung cancer immune checkpoint inhibitors immunotherapy non-small lung cancer chemotherapy |
| title | Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment |
| title_full | Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment |
| title_fullStr | Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment |
| title_full_unstemmed | Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment |
| title_short | Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment |
| title_sort | recent advances in immune checkpoint inhibitors for non small lung cancer treatment |
| topic | lung cancer immune checkpoint inhibitors immunotherapy non-small lung cancer chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1014156/full |
| work_keys_str_mv | AT reemaltaf recentadvancesinimmunecheckpointinhibitorsfornonsmalllungcancertreatment AT reemaltaf recentadvancesinimmunecheckpointinhibitorsfornonsmalllungcancertreatment AT sarmadsherazjadoon recentadvancesinimmunecheckpointinhibitorsfornonsmalllungcancertreatment AT syedaunmuhammad recentadvancesinimmunecheckpointinhibitorsfornonsmalllungcancertreatment AT umairilyas recentadvancesinimmunecheckpointinhibitorsfornonsmalllungcancertreatment AT yongtaoduan recentadvancesinimmunecheckpointinhibitorsfornonsmalllungcancertreatment |